NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis $0.36 0.00 (0.00%) As of 08/11/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Turnstone Biologics Stock (NASDAQ:TSBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Turnstone Biologics alerts:Sign Up Key Stats Today's Range$0.36▼$0.3650-Day Range$0.33▼$0.3852-Week Range$0.29▼$2.42VolumeN/AAverage Volume142,319 shsMarket Capitalization$8.21 millionP/E RatioN/ADividend YieldN/APrice Target$0.45Consensus RatingReduce Company Overview Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. Read More Turnstone Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTSBX MarketRank™: Turnstone Biologics scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingTurnstone Biologics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageTurnstone Biologics has received no research coverage in the past 90 days.Read more about Turnstone Biologics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.32) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turnstone Biologics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turnstone Biologics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurnstone Biologics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently decreased by 8.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently decreased by 8.07%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Turnstone Biologics' insider trading history. Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address TSBX Stock News Headlines$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)June 30, 2025 | globenewswire.comTurnstone Biologics Corp. Enters Merger Agreement with XOMAJune 27, 2025 | tipranks.comNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldman Sachs calls it “The New Oil.” The International Energy Agency says it’s a cornerstone for electricity-related technologies. And the U.S. Department of Energy has officially classified it as “Critical.” Global demand is surging, supply is tightening fast, and one company may be positioned for a potential 3,500% windfall as the world races to secure it. | Behind the Markets (Ad)XOMA stock rises after acquisition of Turnstone BiologicsJune 27, 2025 | au.investing.comTurnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment SlumpsJune 27, 2025 | msn.comTSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to ShareholdersJune 27, 2025 | businesswire.comTurnstone Biologics Corp. (TSBX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comSee More Headlines TSBX Stock Analysis - Frequently Asked Questions How have TSBX shares performed this year? Turnstone Biologics' stock was trading at $0.4969 at the beginning of 2025. Since then, TSBX stock has decreased by 28.6% and is now trading at $0.3550. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) released its earnings results on Friday, August, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.08. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share. Who are Turnstone Biologics' major shareholders? Top institutional investors of Turnstone Biologics include Deltec Asset Management LLC (0.46%). View institutional ownership trends. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Turnstone Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/08/2025Today8/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSBX CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Price Target for Turnstone Biologics$0.45 High Price Target$0.50 Low Price Target$0.40 Potential Upside/Downside+26.8%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.86% Return on Assets-128.13% Debt Debt-to-Equity RatioN/A Current Ratio3.33 Quick Ratio3.70 Sales & Book Value Annual Sales$19.31 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book0.55Miscellaneous Outstanding Shares23,140,000Free Float15,713,000Market Cap$8.21 million OptionableNot Optionable Beta1.36 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:TSBX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredThe New Way Retirees Are Getting Paid Extra Every MonthBloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.